SCHEMBL2970865

SCHEMBL2970865

CCCc1ccc2c(Nc3cc(C)ccc3Sc3ccc(N)cc3)ccnc2n1

nearest known ligand 0.36

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SREBF2 Q12772 2/20 0.36
HTR1A P08908 3/20 0.33
ADRA1D P25100 3/20 0.33
ADRA1A P35348 3/20 0.33
ADRA1B P35368 3/20 0.33
PIM1 P11309 1/20 0.33
AKT2 P31751 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.32
MAPT P10636 1/20 0.32
ATM Q13315 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
PLK4 O00444 1/20 0.30
ICAM1 P05362 1/20 0.30
SELE P16581 1/20 0.30
VCAM1 P19320 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2961869 0.90 PIM1 (0.42) SREBF2HTR1AADRA1DADRA1AADRA1B
SCHEMBL2961431 0.90 PIM1 (0.36) SREBF2HTR1AADRA1DADRA1AADRA1B
SCHEMBL2960105 0.90 HTR1A (0.32) SREBF2HTR1AADRA1DADRA1AADRA1B
SCHEMBL2968588 0.89 SREBF2 (0.38) SREBF2HTR1AADRA1DADRA1AADRA1B
SCHEMBL2962976 0.89 ALDH1A1 (0.35) SREBF2HTR1AADRA1DADRA1AADRA1B
SCHEMBL2019101 0.88 HTR1A (0.33) SREBF2HTR1AADRA1DADRA1AADRA1B
SCHEMBL2022784 0.87 PIM1 (0.39) HTR1AADRA1DADRA1AADRA1BPIM1
SCHEMBL2961153 0.86 SREBF2 (0.44) SREBF2KDM4EALDH1A1MAPT
SCHEMBL2970441 0.85 SLC6A4 (0.40) SREBF2HTR1AADRA1DADRA1AADRA1B
SCHEMBL2969119 0.85 KDM4E (0.40) PIM1AKT2KDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338605-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2012-12-25 US disclosed
US-20100256139-A1 Anti-Viral Compounds ABBOTT LABORATORIES (US) 2010-10-07 US disclosed
EP-1979349-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2010-07-28 EP disclosed
US-7763731-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2010-07-27 US disclosed
EP-1979349-A2 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2008-10-15 EP disclosed
US-20070232645-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-10-04 US disclosed
WO-2007076035-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232645-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 SREBF2 876/4885HTR1A 4760/4885ADRA1D 4585/4885
US-20100256139-A1 Anti-Viral Compounds HAVCR2, MAVS, EIF2AK2 SREBF2 876/4885HTR1A 4760/4885ADRA1D 4585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.